应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
TVRD Tvardi Therapeutics Inc
交易中 12-09 11:50:58 EST
4.20
+0.02
+0.36%
最高
4.29
最低
4.13
成交量
3.80万
今开
4.19
昨收
4.18
日振幅
3.83%
总市值
3,935万
流通市值
3,263万
总股本
938.13万
成交额
15.99万
换手率
0.49%
流通股本
777.87万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌(HCC)二期试验中的主要数据
美股速递 · 11-14
Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌(HCC)二期试验中的主要数据
Tvardi Therapeutics Inc:Piper Sandler将评级从增持下调至中性,目标价从78美元下调至4美元
美股速递 · 10-13
Tvardi Therapeutics Inc:Piper Sandler将评级从增持下调至中性,目标价从78美元下调至4美元
Tvardi Therapeutics股价盘前暴跌66.3%,特发性肺纤维化试验未达预期目标
美股速递 · 10-13
Tvardi Therapeutics股价盘前暴跌66.3%,特发性肺纤维化试验未达预期目标
Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展
美股速递 · 10-13
Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展
加载更多
公司概况
公司名称:
Tvardi Therapeutics Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Tvardi Therapeutics, Inc.于2017年12月20日注册成立,是一家总部位于德克萨斯州休斯顿的特拉华州公司。该公司是一家临床阶段的生物制药公司,专注于开发针对STAT3的新型口服小分子疗法,以治疗具有重大未满足需求的纤维化驱动疾病。基于其创始人的开创性工作和对转录因子STAT3的深刻理解,该公司设计了一种创新方法来直接抑制STAT3,这是一种经过高度验证但在历史上是不可药物的靶点。利用这些专业知识,该公司正在开发具有差异化作用机制和方便的口服给药的STAT3抑制剂管道。该公司的主要候选产品TTI-101目前处于2期临床开发阶段,用于治疗纤维化驱动的疾病,初步重点是特发性肺纤维化、IPF和肝细胞癌、HCC。
发行价格:
--
{"stockData":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":4.195,"timestamp":1765299051017,"preClose":4.18,"halted":0,"volume":38034,"delay":0,"floatShares":7778729,"shares":9381344,"eps":-3.231485,"marketStatus":"交易中","change":0.015,"latestTime":"12-09 11:50:58 EST","open":4.19,"high":4.29,"low":4.13,"amount":159904.938942,"amplitude":0.038278,"askPrice":4.21,"askSize":231,"bidPrice":4.18,"bidSize":88,"shortable":3,"etf":0,"ttmEps":-3.231485,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765314000000},"marketStatusCode":2,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":4.18,"preHourTrading":{"tag":"盘前","latestPrice":4.33,"preClose":4.18,"latestTime":"09:10 EST","volume":1085,"amount":4851.9322950000005,"timestamp":1765289433558},"postHourTrading":{"tag":"盘后","latestPrice":4.18,"preClose":4.18,"latestTime":"16:54 EST","volume":4545,"amount":19000.62,"timestamp":1765230892217},"volumeRatio":0.844464,"impliedVol":1.4743,"impliedVolPercentile":0.2969},"requestUrl":"/m/hq/s/TVRD","defaultTab":"news","newsList":[{"id":"1175189763","title":"Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌(HCC)二期试验中的主要数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1175189763","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175189763?lang=zh_cn&edition=full","pubTime":"2025-11-14 05:26","pubTimestamp":1763069193,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌(HCC)二期试验中的主要数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"1133823913","title":"Tvardi Therapeutics Inc:Piper Sandler将评级从增持下调至中性,目标价从78美元下调至4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133823913","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133823913?lang=zh_cn&edition=full","pubTime":"2025-10-13 22:06","pubTimestamp":1760364390,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc:Piper Sandler将评级从增持下调至中性,目标价从78美元下调至4美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"1177816248","title":"Tvardi Therapeutics股价盘前暴跌66.3%,特发性肺纤维化试验未达预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1177816248","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177816248?lang=zh_cn&edition=full","pubTime":"2025-10-13 19:49","pubTimestamp":1760356154,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics股价在盘前交易中大跌66.3%,该公司的特发性肺纤维化治疗试验未能实现预设目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"1154998252","title":"Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1154998252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154998252?lang=zh_cn&edition=full","pubTime":"2025-10-13 19:30","pubTimestamp":1760355014,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://tvarditherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0691},{"period":"1month","weight":0.0398},{"period":"3month","weight":-0.8686},{"period":"6month","weight":-0.8406},{"period":"1year","weight":-0.5635},{"period":"ytd","weight":-0.7723}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0189},{"period":"3month","weight":0.0512},{"period":"6month","weight":0.1368},{"period":"1year","weight":0.1247},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tvardi Therapeutics, Inc.于2017年12月20日注册成立,是一家总部位于德克萨斯州休斯顿的特拉华州公司。该公司是一家临床阶段的生物制药公司,专注于开发针对STAT3的新型口服小分子疗法,以治疗具有重大未满足需求的纤维化驱动疾病。基于其创始人的开创性工作和对转录因子STAT3的深刻理解,该公司设计了一种创新方法来直接抑制STAT3,这是一种经过高度验证但在历史上是不可药物的靶点。利用这些专业知识,该公司正在开发具有差异化作用机制和方便的口服给药的STAT3抑制剂管道。该公司的主要候选产品TTI-101目前处于2期临床开发阶段,用于治疗纤维化驱动的疾病,初步重点是特发性肺纤维化、IPF和肝细胞癌、HCC。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.042039},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019771},{"month":3,"riseRate":0.583333,"avgChangeRate":0.021822},{"month":4,"riseRate":0.25,"avgChangeRate":-0.048535},{"month":5,"riseRate":0.583333,"avgChangeRate":0.009735},{"month":6,"riseRate":0.583333,"avgChangeRate":-0.017433},{"month":7,"riseRate":0.5,"avgChangeRate":0.091173},{"month":8,"riseRate":0.5,"avgChangeRate":0.010865},{"month":9,"riseRate":0.25,"avgChangeRate":-0.036951},{"month":10,"riseRate":0.5,"avgChangeRate":-0.10272},{"month":11,"riseRate":0.5,"avgChangeRate":0.037928},{"month":12,"riseRate":0.5,"avgChangeRate":-0.018789}],"exchange":"NASDAQ","name":"Tvardi Therapeutics Inc","nameEN":"Tvardi Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tvardi Therapeutics Inc,TVRD,Tvardi Therapeutics Inc股票,Tvardi Therapeutics Inc股票老虎,Tvardi Therapeutics Inc股票老虎国际,Tvardi Therapeutics Inc行情,Tvardi Therapeutics Inc股票行情,Tvardi Therapeutics Inc股价,Tvardi Therapeutics Inc股市,Tvardi Therapeutics Inc股票价格,Tvardi Therapeutics Inc股票交易,Tvardi Therapeutics Inc股票购买,Tvardi Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}